End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
22,600 KRW | +1.57% | +2.03% | -1.31% |
Mar. 14 | Seegene, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Jan. 24 | Seegene Inc. Announces Collaboration with Microsoft to Realize a World Free from All Diseases | CI |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 68.48 times its estimated earnings per share for the ongoing year.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the past year, analysts have significantly revised downwards their profit estimates.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-1.31% | 760M | C+ | ||
-27.67% | 9.87B | A- | ||
-17.30% | 2.73B | C | ||
-11.15% | 2.24B | - | B- | |
-22.32% | 1.63B | C+ | ||
+59.69% | 1.39B | B- | ||
+23.58% | 771M | C- | ||
-28.57% | 516M | C- | ||
+5.37% | 310M | - | - | |
+12.46% | 219M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- A096530 Stock
- Ratings Seegene, Inc.